Overview

Cancer genomics studies how mutations, gene expression, copy-number changes, and other molecular features shape tumor development, patient outcomes, and treatment response. Common approaches include statistical driver and mutation-signature analysis, multi-omics integration, and pathway or regulatory-network models, alongside machine learning on sequencing, pathology images, and scans. Researchers evaluate these methods on resources such as TCGA and clinical cohorts, with tasks including subtype classification, survival prediction, biomarker discovery, and drug response. A central challenge is making predictions that generalize across cancers and incomplete datasets while remaining biologically interpretable and reliable enough for clinical use.

Latest papers

34 papers1 paper in the last four weeks, down 75% on the four weeks before. 0.0% of all new papers.

Feb 26, 2026

Identifying Multi-Hit Cancer Drivers Without Massive Parallelization: A CP, MIP, and Column Generation Framework

Cancer is often driven by specific combinations of an estimated two to nine gene mutations, known as multi-hit combinations. Identifying these multi-hit combinations of gene mutations that drive cancer is critical for understanding carcinogenesis and designing targeted therapies. We formalize this challenge as the Multi-Hit Cancer Driver Set Cover Problem (MHCDSCP), optimizing the selection of gene combinations to maximize tumor coverage while strictly minimizing normal sample misclassification. While existing approaches rely on exhaustive enumeration and massive parallelization, we introduce fast heuristics based on constraint programming and mixed integer programming formulations. Evaluated on real-world cancer genomics data, our framework matches state-of-the-art supercomputing methods using a single commodity CPU in under a minute. We also propose a price-and-branch heuristic which, by solving the root node to optimality, provides the first provably optimal solutions for over half of the benchmark instances, thereby verifying the near-optimality of our fast heuristics. These findings demonstrate that on real-world problem instances, the MHCDSCP is far less computationally demanding than previously believed, providing an accessible baseline that enables the exploration of previously intractable multi-hit modeling assumptions.
Feb 24, 2026

VAE-MS: An Asymmetric Variational Autoencoder for Mutational Signature Extraction

Mutational signature analysis has emerged as a powerful method for uncovering the underlying biological processes driving cancer development. However, the signature extraction process, typically performed using non-negative matrix factorization (NMF), often lacks reliability and clinical applicability. To address these limitations, several solutions have been introduced, including the use of neural networks to achieve more accurate estimates and probabilistic methods to better capture natural variation in the data. In this work, we introduce a Variational Autoencoder for Mutational Signatures (VAE-MS), a novel model that leverages both an asymmetric architecture and probabilistic methods for the extraction of mutational signatures. VAE-MS is compared to with three state-of-the-art models for mutational signature extraction: SigProfilerExtractor, the NMF-based gold standard; MUSE-XAE, an autoencoder that employs an asymmetric design without probabilistic components; and SigneR, a Bayesian NMF model, to illustrate the strength in combining a nonlinear extraction with a probabilistic model. In the ability to reconstruct input data and generalize to unseen data, models with probabilistic components (VAE-MS, SigneR) dramatically outperformed models without (SigProfilerExtractor, MUSE-XAE). The NMF-baed models (SigneR, SigProfilerExtractor) had the most accurate reconstructions in simulated data, while VAE-MS reconstructed more accurately on real cancer data. Upon evaluating the ability to extract signatures consistently, no model exhibited a clear advantage over the others. Software for VAE-MS is available at https://github.com/CLINDA-AAU/VAE-MS.
Dec 23, 2025

EvoXplain: When Machine Learning Models Agree on Predictions but Disagree on Why -- Measuring Mechanistic Multiplicity Across Training Runs

Machine learning models are primarily judged by predictive performance, especially in applied genomics, where explanations are read as biological findings. In practice, reported gene panels are stabilised by averaging, ranking, or taking consensus over the many models a pipeline produces across cross-validation folds, tuning grids, and repeated runs. This raises an overlooked question: when two models achieve high accuracy, do they rely on the same internal logic, or reach the same outcome via different mechanisms? We introduce EvoXplain, a diagnostic framework that measures whether a pipeline's explanation is uniquely determined across repeated training and model selection. Rather than analysing a single trained model, EvoXplain treats explanations as samples drawn from the training and model selection pipeline itself, without aggregating predictions or constructing ensembles, and examines whether they form a single coherent explanatory basin or separate into multiple structured basins. We evaluate EvoXplain on a TCGA pan-cancer cohort and a within-cancer breast-cancer subtype task, using elastic-net Logistic Regression and gradient-boosted trees. Although all models reach about 98% accuracy, explanation structure differs across pipelines. Holding the data split fixed and varying only the regularisation strength, equally accurate Logistic Regression models separate into a few discrete, reproducible basins that recur across 100 data splits and carry distinct biological content, while the gradient-boosted pipeline converges to one basin. The same multiplicity appears within a single cancer subtype, from the ordinary tuning step alone. EvoXplain makes explanatory structure visible, revealing when an averaged consensus corresponds to no single trained model, and reframes interpretability as a property of the training pipeline rather than of any single model.
May 17, 2021

Cross-Cluster Weighted Forests

Building trustworthy machine learning algorithms for biological applications requires adapting to data heterogeneity from different sources, batches, distributions, or studies. We propose the 'Cross-Cluster Weighted Forest' (CCWF), an ensembling approach that explicitly leverages heterogeneity in the feature distribution to produce more accurate and more generalizable predictors than the standard Random Forest in cases when data can be naturally clustered. CCWF generalizes the RF architecture to an outer unsupervised layer, supervised subtasks, and ensembling. Specifically it involves unsupervised clustering of the training data, fitting a Random Forest on each cluster, and combining the forests via stacked regression weights that reward cross-cluster generalizability. We provide a theoretical analysis of an analytically tractable forest model showing that cluster-based ensembling is asymptotically more accurate than training a single forest on the full data, with the gain driven by bias reduction. In simulations, we find that CCWF is robust across data-generating regimes and outcome models; furthermore, we explore the influence of data partitioning and ensemble weighting strategies on the benefits of our method. Finally, we apply our approach to cancer molecular profiling and gene expression datasets that are naturally divisible into clusters; in both simulations and real data examples, we illustrate that our approach outperforms classic Random Forest by margins of 30-40%, aligning with our theoretical results. Overall, we show that CCWF provides a statistically grounded prediction algorithm for data spanning multiple domains or sub-populations, a structure common in biological applications.